Incyte Genomics (INCY) Stock: Buy, Sell, or Hold?
INCY - Incyte Genomics Inc
$121.47
-1.81 (-1.47%)
âŧ
5d:
-5.1%
30d:
+0.58%
90d:
+12.65%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 27, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 4, 2026 at $126.75 · last confirmed Sep 9, 2026
Strength: 5.2/10
Get Alerted When INCY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: INCY is fairly priced but lacks strong directional signals. At 3.8% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: INCY is fairly priced but lacks strong directional signals. At 3.8% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$211.10
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$131.08
7.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INCY is currently trading at $121.47, which is considered slightly low relative to its 30-day fair value range of $120.62 to $127.47. From a valuation perspective, the stock is trading at a premium (Forward PE: 13.7) compared to its historical average (12.2). At these levels, the market is pricing in 3.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, INCY is in a strong uptrend. The price is currently testing key support at $121.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INCY scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INCY is in a strong uptrend. The price is currently testing key support at $121.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INCY scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$120.62 -
$127.47
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
53.3%
Protect Your Profits
Holding INCY? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($127.74)
- NEUTRAL: Market pricing in 3.8% annual earnings growth - fairly valued
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$120.62 -
$127.47
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$121.42
Resistance Level
$130.00
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.67
Wall Street Target
$127.74
(+5.2%)
Revenue Growth (YoY)
37.7%
Earnings Growth (YoY)
37.7%
Profit Margin
27.7%
Valuation Premium vs History
+3.8% premium
PE vs Historical
13.7 vs 12.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.8%
(market-implied from PE analysis)
1-Year Target
$126.09
(+4%)
2-Year Target
$130.88
(+8%)
3-Year Target
$135.85
(+12%)
3-Yr Target (if PE normalizes)
(PE: 14â12)
PE COMPRESSION
$121.24
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 157.1%)
$604.87
(+398%)
Base:
(SPY PE: 13.7, Growth: 157.1%)
$409.96
(+238%)
Bear:
(PE: 11.6, Growth: 157.1%)
$348.47
(+187%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 16.05 | Current EPS (TTM): $7.68
Bull Case
$156.89
(+29%)
Analyst growth 15.7%, PE expands to 17.7
Base Case
$142.63
(+17%)
Market implied 15.7%, PE stable at 16.1
Bear Case
$83.83
(-31%)
Severe decline -20.0%, PE contracts to 13.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 7:19 PM ET
Data refreshes hourly during market hours. Next update: 8:19 PM
Data refreshes hourly during market hours. Next update: 8:19 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INCY showing a specific setup today?
Insider Activity (6 Months)
1
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Pablo J Cagnoni
SELL
18667 shares
2026-04-17
Ro Khanna
BUY
2026-03-30
Pablo J Cagnoni
SELL
18667 shares
2026-03-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
Advanced INCY Option Strategies
Professional options setups generated by AI based on today's INCY price and gamma walls.
